AlphAIAlphAI — Financial news for AI agents
rttnews.comOCT 282 min read$GMAB

Genmab's Petosemtamab Combination Improves Survival In Phase 3 Head And Neck Cancer Trial; Stock Up

Genmab (GMAB) reported positive Phase 3 trial results for Petosemtamab combined with Keytruda in head and neck cancer, showing a 50% reduction in death risk and improved tumor response. The combination met primary endpoints and was well tolerated. GMAB plans regulatory discussions and further trials. The stock is up 28.89% at $57.53.

Original reporting
rttnews.com
Published Oct 28, 2026, 3:29 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 3:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Genmab's Petosemtamab Combination Improves Survival In Phase 3 Head And Neck Cancer Trial; Stock Up — source image
Source · rttnews.com
Decision brief

The 30-second read

$GMABBullishHigh
01

Why it matters

The trial met its primary endpoints with a hazard ratio of 0.50 and a statistically significant improvement in response rate, positioning the combo for potential regulatory filing and market adoption.

02

Market read

First‑report of pivotal trial data is a material catalyst for Genmab and may influence peer valuations in the oncology biotech space.

03

What to watch

Potential competition from other PD‑L1 combos and the need for further safety data could temper long‑term upside.

Relevance 7/10Novelty 9/10Timing: today

Background

Genmab A/S (GMAB) is a Danish biotech focused on antibody therapeutics. The LiGeR‑HN1 trial evaluated its investigational bispecific antibody Petosemtamab plus pembrolizumab in first‑line head and neck cancer.

Company-level read

Ticker impact

$GMABBullishHigh confidence
Context

Genmab reported positive Phase 3 trial results for its bispecific antibody Petosemtamab combined with Keytruda, showing a 50% reduction in risk of death and improved overall survival.

Expected impact

upward pressure as the market prices in the survival benefit and potential regulatory filing.

Evidence & confidence

First disclosure of Phase 3 efficacy data for a late‑stage oncology asset; stock already up ~29% on the news, indicating strong market reaction.

Market effects

Sector

Boosts sentiment for the oncology biotech sector and may lift peer companies developing bispecific antibodies.

Regional

Positive for European biotech markets where Genmab is listed.

Global

Adds to the pipeline momentum for immuno‑oncology therapies worldwide.

Counterpoint

What could challenge this read

If the trial data does not translate into regulatory approval or commercial uptake, the rally could be short‑lived.

Key entities

  • company
    Genmab A/S

    Danish biotech developing bispecific antibodies.

  • drug
    Petosemtamab

    Investigational bispecific antibody targeting EGFR and LGR5.

  • drug
    Keytruda (pembrolizumab)

    PD‑L1 inhibitor used in the combination regimen.

Read at source← All news

StoryGenmab reports 50% mortality cut in Phase 3 head‑and‑neck cancer trial

Also covered by

2 outlets

Related articles

OCT 28
$GMABHighAI 9/10

Genmab reports 50% lower death risk in Phase 3 trial

Genmab reported that its petosemtamab combination reduced the risk of death by 50% in a Phase 3 head-and-neck cancer trial, meeting both primary endpoints. The study involved 699 patients. Genmab's shares rose 15.22% to $51.47 on Wednesday. The company plans to discuss results with global regulators.

mugglehead.com2 min
OCT 28
$GMABHigh

Genmab A/S: Genmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in First-Line R/M Patients with PD-L1+ Head and Neck Cancer

Genmab (GMAB) reported positive Phase 3 trial results for petosemtamab in combination with pembrolizumab, showing a 50% reduction in death risk for PD-L1+ head and neck cancer patients. The trial met both primary endpoints, and the company plans to engage regulators and present full results. Petosemtamab is also being evaluated in other Phase 3 trials for different cancers.

finanznachrichten.de2 min
OCT 28
$GMABHighAI 9/10

Why is Genmab stock surging today?

Genmab's stock rose 16.8% after its Phase 3 LiGeR-HN1 trial showed a 50% reduction in death risk for a combination treatment. Analysts upgraded the stock, with JPMorgan raising its price target to DKK 3,500 and TD Cowen to $52.00. The trial results were well-received, with no new safety concerns.

investing.com2 min
OCT 28
$GMABHigh

Genmab’s petosemtamab trial cuts death risk by 50% in cancer

Genmab A/S (GMAB) reported that its Phase 3 trial for petosemtamab met primary endpoints, reducing death risk by 50% in head and neck cancer patients. The combination therapy showed significant improvements in overall survival and response rates, with a hazard ratio of 0.50 and an objective response rate odds ratio of 3.17. The company plans regulatory submissions and further trial evaluations. Head and neck squamous cell carcinoma is the seventh most common cancer globally.

investing.com2 min